EXENATIDE (BYETTA) VS PRAMLINTIDE (SYMLIN)

艾塞那肽 (BYETTA) VS 普兰林肽 (SYMLIN)

• 批准号: 8166744
• 负责人: RUBINA A HEPTULLA
• 金额: $ 1.98万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166744
• 关键词: Adolescent; Adult; Animals; Apoptosis; Beta Cell; Child; Childhood; Computer Retrieval of Information on Scientific Projects Database; Diabetes Mellitus; Diabetic Angiopathies; Dietary Carbohydrates; Disease; Funding; Gastroparesis; Glucagon; Glucose; Grant; Hyperglycemia; Institution; Insulin; Insulin-Dependent Diabetes Mellitus; Mono-S; New Agents; Pramlintide; Protocols documentation; Reporting; Research; Research Personnel; Resources; Source; United States National Institutes of Health; analog; comparative efficacy; exenatide; glucagon-like peptide 1; glycemic control; hyperglucagonemia; improved; islet amyloid polypeptide; tool

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Type 1 diabetes mellitus (T1DM) is currently managed using modulation of dietary carbohydrates and insulin. Paradoxical post-meal hyperglucagonemia is associated with post-prandial hyperglycemia in T1DM. Glucagon suppressors such as the amylin analog, pramlintide, and the glucagon like peptide-1 (GLP-1) analog, exenatide, are new agents approved for use in adults with diabetes. We have previously demonstrated pramlintide reduces post-prandial hyperglycemia by decreasing glucagon and delaying gastric emptying in adolescents with T1DM. GLP-1 in animal studies has been shown to increase beta cell mass and decrease apoptosis. Only limited information is available on the use of GLP-1 in T1DM. No studies have been reported to determine if pramlintide and exenatide have similar effects on glycemic control in T1DM. The overall aim of this proposal is to develop safe and effective strategies targeting glucagon and improving glycemic control in pediatric T1DM. In current protocol, we hypothesize that exenatide/pramlintide will be better than insulin alone in improving glycemic control in longstanding T1DM. Secondarily comparisons between pramlintide and exenatide will be undertaken. Uses of exenatide and/or pramlintide provide us with potentially new tools to improve glycemic control in children and adolescents with T1 DM and thus reduce associated long-term microvascular complications of this debilitating disease. Postprandial glucose excursions improve with adjunctive therapy of exenatide or pramlintide with insulin as compared to mono-therapy of insulin. 1) To examine the effect of exenatide vs pramlintide adjunctive therapy in addition to insulin on glycemic control in T1DM as compared to mono-therapy of insulin. 2) To compare the efficacy of pramlintide vs exenatide when combined with insulin on glycemic control in T1DM.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 1型糖尿病（T1DM）目前是使用饮食中碳水化合物和胰岛素的调节来管理的。悖论后的后高葡萄糖血症与T1DM中的餐后高血糖有关。胰高血糖素抑制剂，例如氨基蛋白类似物，pramlintide和胰高血糖素（如肽-1（GLP-1）类似物），是艾鉴定的，是批准用于糖尿病成人的新药物。我们以前曾证明，pramlintide通过减少胰高血糖素并延迟T1DM青少年的胃排空来降低餐后高血糖。在动物研究中，GLP-1已显示可增加β细胞量并减少凋亡。只有在T1DM中使用GLP-1的有限信息。尚无据报道，确定pramlintide和Etenatide对T1DM中血糖控制的影响是否相似。该提案的总体目的是制定针对胰高血糖素的安全有效策略，并改善小儿T1DM的血糖控制。在当前方案中，我们假设艾替尼/pramlintide在改善长期T1DM的血糖控制方面将比单独的胰岛素更好。其次，将进行pramlintide和Etenatide之间的比较。亚烯酰胺和/或pramlintide的用途为我们提供了潜在的新工具，以改善具有T1 DM的儿童和青少年的血糖控制，从而减少了这种令人衰弱的疾病的相关长期的长期微血管并发症。 与胰岛素单疗法相比，餐后葡萄糖偏移通过胰岛素或胰岛素的辅助治疗改善。 1）与胰岛素单疗法相比，除了胰岛素对T1DM的血糖控制外，艾替肽与pramlintide辅助疗法的影响。 2）当与胰岛素结合在T1DM中的血糖控制中，比较pramlintide vs烯烃的功效。